Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours
with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours
|
II
|
HUG
|
CAAA604A12101: A phase I, open-label, multi-center study to evaluate the safety, tolerability, dosimetry and preliminary activity of [177Lu]Lu-FF58 in patients with selected advanced solid tumors
Locally advanced unresectable or metastatic PDAC and GEA, Recurrent GBM
|
I
|
HUG
|
INCA 33890-101: A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Part 1a: Histologically or cytologically confirmed advanced or metastatic solid tumors as follows: BC (pure small-cell carcinoma, pure adenocarcinoma, and pure squamous cell carcinoma are exlucded) - CESC - ESCA - GC - GEJ - Mel - MPM - NSCLC (mixed small-cell and non-small cell lung cancer histology is exlcluded - tumors should not exhibit mutations in EFGR, ALK, ROS1, BRAF) - OC (Sertoli-Leydic or germ cell cancers are excluded) - RCC - SCCHN (Carcinoma of the nasopharynx, salivary gland, or nonsquamous histologies are excluded) - TNBC - PAAD - CRC. Part1b: same as part 1a, plus dMMR/MSI-H CRC and MSS-CRC
|
I
|
CHUV
|
INCB 123667-101: A phase I, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors
Histologically or citologically confirmed advanced or metastatic solid tumors
|
I
|
CHUV
|
KISIMA-01: An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, With or Without BI 754091, in Patients With Stage IV Colorectal Cancer
Stage IV colorectal cancer
|
I
|
HUG
|
KISIMA-02 A Phase 1b Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma
KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma
|
I
|
HUG
|
MK-3475U06: A Phase 1/2 Open-Label, Umbrella Platform Design of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer
Advanced Esophageal Cancer
|
I, II
|
HUG
|
NAB-PIPAC: A phase IB trial of intraperitoneal cisplatin and Nab-Paclitaxel administered by pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity
Peritoneal carcinomatosis from pancreatic, oesogastric, epithelial ovarian cancers or primitive peritoneal mesothelioma
|
I
|
CHUV, HUG
|
ORIGAMA an interventional platform study investigating the impact of digital health solutions on health outcomes and health-care resource utilization in participants receiving systemic treatment in clinical practice
mNSCLC, ES-SCLC, HCC child Pugh A
|
II, III
|
HUG
|
PEMREC:A Phase II Study to Evaluate Safety and Efficacy of Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer
Localised MSS Rectal Cancer
|
II
|
HUG
|
SGNB6A-001: A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
NSCLC, HNSCC, ESCC, HGSOC, cSCC, cancer du sein HER2 négative avancé, Adénocarcinome oesophagien/adénocarci-nome gastro-oesophagien, cancer de la vessie, cancer degestif, cancer du col de l'utérus
|
I
|
CHUV
|
TAK-676-1002: An open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-676 as single agent and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors
Part 2: Histologically confirmed metastatic or unresectable recurrent SCCHN considered incurable by local therapies (oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, paranasal sinues) - Part 3: Histologically confirmed recurrent locally advanced or metastatic MSI-H/dMMR or MSS/pMMR CRC
|
I
|
CHUV, HUG
|